CORC

在结果中检索

CORC

浏览/检索结果: 共16条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer 期刊论文
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 卷号: 380, 期号: 7
作者:  Wuelfing, P.;  Mano, M. S.;  Loibl, S.;  Mamounas, E. P.;  Untch, M.
收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05
KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer 会议论文
作者:  Mamounas, Eleftherios P.;  Geyer, Charles E., Jr.;  Huang, Chiun-Sheng;  Mano, Max S.;  Loibl, Sibylle
收藏  |  浏览/下载：21/0  |  提交时间：2019/12/05
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE 会议论文
作者:  Geyer, C. E., Jr.;  Huang, C-S;  Mano, M. S.;  Loibl, S.;  Mamounas, E. P.
收藏  |  浏览/下载：27/0  |  提交时间：2019/12/05
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials 期刊论文
2019, 卷号: 393, 期号: 10179, 页码: 1440-1452
作者:  Boddington, C.;  Bradley, R.;  Braybrooke, J.;  Burrett, J.;  Clarke, M.
收藏  |  浏览/下载：45/0  |  提交时间：2020/01/03
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 期刊论文
2018, 卷号: 19, 期号: 1, 页码: 27-39
作者:  Alberro, J. A.;  Ballester, B.;  Deulofeu, P.;  Fabregas, R.;  Fraile, M.
收藏  |  浏览/下载：46/0  |  提交时间：2020/01/03
Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) 会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:  Lambertini, M.;  Campbell, C.;  Bines, J.;  Korde, L.;  Delso, M. A. Izquierdo
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03
Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) 期刊论文
2017, 卷号: 28
作者:  Lambertini, M.;  Campbell, C.;  Bines, J.;  Korde, L.;  Delso, M. A. Izquierdo
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial 期刊论文
2017, 卷号: 35
作者:  Huober, Jens Bodo;  Holmes, Eileen McCormick;  Baselga, Jose;  De Azambuja, Evandro;  Untch, Michael
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant tre 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20
作者:  Moreno-Aspitia, Alvaro;  Holmes, Eileen McCormick;  Jackisch, Christian;  De Azambuja, Evandro;  Boyle, Frances M.
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20
作者:  Huober, Jens Bodo;  Holmes, Eileen McCormick;  Baselga, Jose;  De Azambuja, Evandro;  Untch, Michael
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/04

©版权所有 ©2017 CSpace - Powered by CSpace